TrialOncoimmunology2026

Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC).

Rachel E Sanborn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.